Overview

Safety of CRIS100 on Treatment Spinal Cord Injury

Status:
Not yet recruiting

Trial end date:
2024-09-15

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to test CRIS100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer are: - safety of CRIS100 - efficacy of CRIS100 Participants will receive 75 mcg CRIS100 in the epicenter of the spinal injury, within 72 hours of the trauma.

Phase:

Early Phase 1

Details

Lead Sponsor:

Cristália Produtos Químicos Farmacêuticos Ltda.